Vliv glukózy na expresi endoglinu a biomarkerů endotelové dysfunkce u endotelových buněk

• Název práce v češtině: Vliv glukózy na expresi endoglinu a biomarkerů endotelové dysfunkce u endotelových buněk
• Název v anglickém jazyce: Effect of glucose treatment on endoglin and biomarkers of endothelial dysfunction in endothelial cells
• Akademický rok vypsání: 2018/2019
• Typ práce: diplomová práce
• Jazyk práce: čeština
• Ústav: Katedra biologických a lékařských věd (16-16150)
• Vedoucí / školitel: prof. PharmDr. Petr Nachtigal, Ph.D.
• Řešitel: skrytý - zadáno vedoucím/školitelem
• Datum přihlášení: 27.09.2018
• Datum zadání: 12.02.2020
• Datum a čas obhajoby: 03.06.2020 08:00
• Datum odevzdání elektronické podoby: 04.05.2020
• Datum proběhlé obhajoby: 03.06.2020
• Oponenti: RNDr. Ivana Němečková, Ph.D.

Zásady pro vypracování

1. Teoretická rešerše literatury
2. Experimentální část v laboratoři
3. Sepsání diplomové práce
4. Obhajoba diplomové práce

Seznam odborné literatury

1. Nachtigal P, Zemankova Vecerova L, Rathouska J, Strasky Z. The role of endoglin in atherosclerosis. Atherosclerosis. 2012;224(1):4-11. doi: 10.1016/j.atherosclerosis.2012.03.001. PubMed PMID: 22460049.
2. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642-9. Epub 2006/06/06. doi: nm1429 [pii]
10.1038/nm1429. PubMed PMID: 16751767.
3. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010;70(10):4141-50. Epub 2010/04/29. doi: 0008-5472.CAN-09-4466 [pii]
10.1158/0008-5472.CAN-09-4466. PubMed PMID: 20424116.
4. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood. 2002;100(12):4001-10. Epub 2002/11/16. doi: 10.1182/blood.V100.12.4001
100/12/4001 [pii]. PubMed PMID: 12433697.
5. Ollauri-Ibanez C, Lopez-Novoa JM, Pericacho M. Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies. Expert Opin Biol Ther. 2017;17(9):1053-63. Epub 2017/06/29. doi: 10.1080/14712598.2017.1346607. PubMed PMID: 28656781.
6. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 2002;277(46):43799-808. Epub 2002/09/14. doi: 10.1074/jbc.M207160200
M207160200 [pii]. PubMed PMID: 12228247.
7. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412(3):477-84. Epub 2008/04/09. doi: 10.1042/BJ20080476. PubMed PMID: 18393939; PubMed Central PMCID: PMCPMC2474706.
8. Valbuena-Diez AC, Blanco, F.J., Oujo, B. et al. Oxysterol-induced soluble endoglin release and its involment in hypertension. Circulation. 2012:2612-24.
9. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005;96(6):684-92. Epub 2005/02/19. doi: 01.RES.0000159936.38601.22 [pii]
10.1161/01.RES.0000159936.38601.22. PubMed PMID: 15718503.
10. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 2004;18(3):609-11. Epub 2004/01/22. doi: 10.1096/fj.03-0197fje
03-0197fje [pii]. PubMed PMID: 14734648.
11. Rossi E, Sanz-Rodriguez F, Eleno N, Duwell A, Blanco FJ, Langa C, et al. Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood. 2013;121(2):403-15. Epub 2012/10/18. doi: 10.1182/blood-2012-06-435347
blood-2012-06-435347 [pii]. PubMed PMID: 23074273.
12. Rossi E, Pericacho M, Bachelot-Loza C, Pidard D, Gaussem P, Poirault-Chassac S, et al. Human endoglin as a potential new partner involved in platelet-endothelium interactions. Cell Mol Life Sci. 2018;75(7):1269-84. Epub 2017/10/31. doi: 10.1007/s00018-017-2694-7. PubMed PMID: 29080903; PubMed Central PMCID: PMCPMC5843676.
13. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8(11):1211-7. Epub 2002/11/02. doi: 10.1038/nm1102-1211
nm1102-1211 [pii]. PubMed PMID: 12411947.
14. Levitan I, Volkov, S., Subbaiah, P.V. Oxidized LDL: Diversity, Patterns of Recognition, and Pathophysiology. Antioxidants & Redox Signaling. 2010:39-75.
15. Chalubinski M, Zemanek K, Skowron W, Wojdan K, Gorzelak P, Broncel M. The effect of 7-ketocholesterol and 25-hydroxycholesterol on the integrity of the human aortic endothelial and intestinal epithelial barriers. Inflamm Res. 2013;62(12):1015-23. doi: 10.1007/s00011-013-0660-x. PubMed PMID: 24077843; PubMed Central PMCID: PMCPMC3826051.
16. Olkkonen VM, Beaslas, O., Nissila, E. Oxysterols and their cellular effectors. Biomolecules. 2012:76-103.
17. Hayden JM, Brachova L, Higgins K, Obermiller L, Sevanian A, Khandrika S, et al. Induction of monocyte differentiation and foam cell formation in vitro by 7-ketocholesterol. J Lipid Res. 2002;43(1):26-35. Epub 2002/01/17. PubMed PMID: 11792719.
18. Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243(2):383-8. doi: 10.1016/j.atherosclerosis.2015.10.003. PubMed PMID: 26520890.
19. Strasky Z, Vecerova L, Rathouska J, Slanarova M, Brcakova E, Kudlackova Z, et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ J. 2011;75(7):1747-55. PubMed PMID: 21576826.
20. Zemankova L, Varejckova M, Dolezalova E, Fikrova P, Jezkova K, Rathouska J, et al. Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin. J Physiol Pharmacol. 2015;66(3):403-13. PubMed PMID: 26084222.
21. Ruiz-Remolina L, Ollauri-Ibanez C, Perez-Roque L, Nunez-Gomez E, Perez-Barriocanal F, Lopez-Novoa JM, et al. Circulating soluble endoglin modifies the inflammatory response in mice. PLoS One. 2017;12(11):e0188204. Epub 2017/11/18. doi: 10.1371/journal.pone.0188204. PubMed PMID: 29145462; PubMed Central PMCID: PMCPMC5690682.
22. Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci U S A. 1994;91(10):4431-5. PubMed PMID: 8183926.
23. Csanyi G, Gajda M, Franczyk-Zarow M, Kostogrys R, Gwozdz P, Mateuszuk L, et al. Functional alterations in endothelial NO, PGI(2) and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins & other lipid mediators. 2012;98(3-4):107-15. doi: 10.1016/j.prostaglandins.2012.02.002. PubMed PMID: 22465673.
24. Jawien J, Csanyi G, Gajda M, Mateuszuk L, Lomnicka M, Korbut R, et al. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Eur J Pharmacol. 2007;556(1-3):129-35. PubMed PMID: 17174298.
25. Yamagata K, Tanaka N, Suzuki K. Epigallocatechin 3-gallate inhibits 7-ketocholesterol-induced monocyte-endothelial cell adhesion. Microvasc Res. 2013;88:25-31. Epub 2013/04/10. doi: 10.1016/j.mvr.2013.03.006. PubMed PMID: 23567873.
26. Kij A, Mateuszuk L, Sitek B, Przyborowski K, Zakrzewska A, Wandzel K, et al. Simultaneous quantification of PGI2 and TXA2 metabolites in plasma and urine in NO-deficient mice by a novel UHPLC/MS/MS method. J Pharm Biomed Anal. 2016;129:148-54. Epub 2016/07/18. doi: 10.1016/j.jpba.2016.06.050. PubMed PMID: 27424195.
27. Przyborowski K, Wojewoda M, Sitek B, Zakrzewska A, Kij A, Wandzel K, et al. Effects of 1-Methylnicotinamide (MNA) on Exercise Capacity and Endothelial Response in Diabetic Mice. PLoS One. 2015;10(6):e0130908. Epub 2015/06/27. doi: 10.1371/journal.pone.0130908. PubMed PMID: 26115505; PubMed Central PMCID: PMCPMC4482656.
28. Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyspler R, Dolezelova E, et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15-25. Epub 2018/02/21. doi: 10.1016/j.atherosclerosis.2018.02.008. PubMed PMID: 29459262.
29. Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, et al. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS One. 2015;10(3):e0119665. doi: 10.1371/journal.pone.0119665. PubMed PMID: 25768936; PubMed Central PMCID: PMC4359129.
30. Dopico AM, Bukiya AN, Jaggar JH. Calcium- and voltage-gated BK channels in vascular smooth muscle. Pflugers Arch. 2018. Epub 2018/05/12. doi: 10.1007/s00424-018-2151-y. PubMed PMID: 29748711.